Status:
COMPLETED
Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants
Lead Sponsor:
Pfizer
Collaborating Sponsors:
European Society for Blood and Marrow Transplantation
Conditions:
Prophylaxis Of Invasive Fungal Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To prevent recurrence of invasive fungal infection in patients with allogeneic stem cell transplants
Eligibility Criteria
Inclusion
- Patients with proven or probable IFI in previous 12 months receiving an allogenic stem cell transplant for any haematological disease
Exclusion
- Pregnant or lactating women
- Severe disease other tham the underlying condition
- Active, symptomatic uncontrolled Invasive Fungal Infection
- Any evidence of active fungal disease as defined by MSG-EORTC criteria
- Concomitant use of Voriconazole 36 hours before chemotherapy until 48 hours after chemotherapy
- Other medical conditions, including HIV positive serology that would interfere with the evaluation of therapeutic response or safety of study drug
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00143312
Start Date
February 1 2005
End Date
April 1 2008
Last Update
October 6 2009
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Leuven, Belgium, 3000
2
Pfizer Investigational Site
Marseille, Cedex 09, France, 13273
3
Pfizer Investigational Site
Créteil, France, 94010
4
Pfizer Investigational Site
Nantes, France, 44035 cedex